GlaxoSmithKline Renews and Expands Global License for Simulations Plus Software

Company Adds Parsippany, NJ Site to Multi-year Agreement
LANCASTER, Calif.--(Business Wire)--
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of
software for pharmaceutical discovery and development, today announced
that GlaxoSmithKline (GSK) has renewed its global multi-year license
for Simulations Plus software and has added a new site at its
Parsippany, NJ location.

Ron Creeley, vice president of marketing and sales for Simulations
Plus, said: "GSK was one of the first GastroPlus(TM) customers back in
1998 and probably has the largest number of scientists who have gone
through GastroPlus training over the years - somewhere in the
hundreds. GSK's scientists are among the most expert users of
GastroPlus in the industry, and they have published scientific papers
and posters referencing their use of GastroPlus in their important
research."

Walt Woltosz, chairman and chief executive officer of Simulations
Plus, added: "We appreciate the continued confidence GSK has shown in
Simulations Plus over the years, as well as suggestions for
improvement they have provided that are now standard features in our
programs. This is a time of growing use of simulation and modeling
tools in pharmaceutical research, and GSK has been one of the
companies at the forefront. We look forward to continuing the
excellent relationships we have with GSK scientists worldwide."

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking
drug discovery and development software, which is licensed to and used
in the conduct of drug research by pharmaceutical, biotechnology, and
drug delivery companies worldwide. The Company has two other
businesses, Words+, Inc. and FutureLab(TM), which are based on its
proprietary software technologies. Simulations Plus, Inc., is
headquartered in Southern California and trades on the NASDAQ under
the symbol "SLP." For more information, visit our Web site at
www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 - With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Our actual future
results could differ significantly from those statements. Factors that
could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, and a sustainable
market. Further information on our risk factors is contained in our
quarterly and annual reports as filed with the Securities and Exchange
Commission.

Simulations Plus, Inc.
Investor Relations
Ms. Renee Bouche
661-723-7723
info@simulations-plus.com

Copyright Business Wire 2008